局部晚期直肠癌原发灶放疗加量的系统综述与实践荟萃分析
该系统综述与荟萃分析检索PubMed和EMBASE,纳入83项描述性分析研究和78项荟萃分析研究,评估局部晚期直肠癌原发灶外照射放疗加量的技术参数及其对肿瘤学结局的影响。结果显示各研究放疗参数异质性大,IMRT/VMAT、同步加量、剂量递增(BED>74 Gy)及诱导联合巩固化疗与更高的病理完全缓解率显著相关,但未发现与临床完全缓解或局部复发率的显著关联。
要点
- 直肠癌原发灶放疗加量实践异质性大,亟需标准化。
- IMRT/VMAT、同步加量、BED>74 Gy与更高病理完全缓解率相关。
- 未发现加量参数与临床完全缓解或局部复发率显著相关。
核心结论
- 直肠癌原发灶放疗加量已在真实世界实践中应用,但技术异质性大,亟需标准化。
- IMRT/VMAT、同步加量及剂量递增与更高的病理完全缓解率相关,应考虑纳入未来直肠加量指南。
- 上述发现需谨慎解读,因未对可能影响反应率和肿瘤学结局的临床、肿瘤或患者相关参数进行调整。
研究设计与样本
- 遵循PRISMA指南,在PubMed和EMBASE检索「rectum」「radiotherapy」「boost」相关文献(PROSPERO注册号CRD42023444685)。
- 纳入报告局部晚期直肠癌原发灶外照射放疗加量且符合质量标准的的研究。
- 描述性分析提取放疗技术、准备、加量靶区勾画、剂量、化疗及随访数据。
- 采用混合效应荟萃分析模型评估所选参数对完全缓解率和局部复发率的影响。
- 按治疗意图(计划手术或等待观察)分别分析研究。
主要发现
- 从3904篇文献中纳入83项描述性分析研究和78项荟萃分析研究。
- 各研究间放疗参数存在显著异质性。
- IMRT/VMAT与更高的病理完全缓解率显著相关(p=0.007)。
- 同步加量与更高的病理完全缓解率显著相关(p=0.020)。
- 剂量递增(BED>74 Gy)及诱导联合巩固化疗分别与更高的病理完全缓解率显著相关(p=0.035;p=0.023)。
关键数值与推荐
- 病理完全缓解率在IMRT/VMAT组显著更高(p=0.007)。
- 病理完全缓解率在同步加量组显著更高(p=0.020)。
- 病理完全缓解率在BED>74 Gy剂量递增组显著更高(p=0.035)。
- 病理完全缓解率在诱导联合巩固化疗组显著更高(p=0.023)。
临床怎么用
- 局部晚期直肠癌原发灶放疗加量可考虑采用IMRT/VMAT技术、同步加量及BED>74 Gy剂量递增以提高病理完全缓解率。
- 诱导联合巩固化疗联合放疗加量可能提高病理完全缓解率,但需结合患者具体情况个体化决策。
- 因缺乏与临床完全缓解及局部复发率的显著关联证据,加量策略对等待观察资格的影响尚不明确。
局限性
- 未对可能影响反应率和肿瘤学结局的临床、肿瘤或患者相关参数进行调整。
- 各研究间放疗参数异质性大,可能影响结果解释。
- 研究按治疗意图(计划手术或等待观察)分别分析,可能限制跨组比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In locally advanced rectal cancer (LARC), increasing the complete response (CR) rate after total neo-adjuvant treatment may increase the patient eligibility for non-operative management ("watch and wait", W&W). Although a radiotherapy (RT) boost to the primary tumour may enhance CR rates, clear guidelines are currently lacking. This systematic review and meta-analysis investigate the technical parameters used for rectal boost RT and assess their impact on oncological outcomes. METHODS: Following PRISMA guidelines, the terms "rectum," "radiotherapy," and "boost" were searched in PubMed and EMBASE (PROSPERO: CRD42023444685). Studies reporting on external beam RT boost to the primary tumour in LARC and meeting quality criteria were included. Descriptive analyses extracted data on RT technique, preparation, boost delineation, dose, chemotherapy, and follow-up. A mixed-effects meta-analysis model evaluated the impact of selected parameters on CR and local recurrence rate (LRR). Studies were analysed separately based on treatment intent: planned surgery or W&W. RESULTS: Out of 3904 references, 83 were included in the descriptive analysis and 78 in the meta-analysis. Substantial variability in RT parameters was observed across studies. Pathologic CR rates were significantly higher with intensity-modulated/volumetric-modulated arc RT (IMRT/VMAT, p = 0.007), simultaneous boost (p = 0.020), dose escalation (Biological equivalent dose > 74 Gy, p = 0.035), and the combination of induction and consolidation chemotherapy (p = 0.023). No significant associations were found for clinical CR or LRR. CONCLUSION: While rectal RT boost is already part of real-world practices, the wide heterogeneity in techniques highlights the urgent need for standardisation. Our meta-analysis suggests that IMRT/VMAT, simultaneous boost, and dose escalation are associated with higher pathological CR rates and should be considered in future rectal boost guidelines. These findings, however, warrant careful interpretation due to the absence of adjustments for clinical, tumoral, or patient-related parameters that may also influence response rate and oncological outcomes.
引用
- Pierrard J, Donnay L, Collard A, et al. Radiotherapy boost to the primary tumour in locally advanced rectal cancer: Systematic review of practices and meta-analysis. Clin Transl Radiat Oncol. 2025. PMID: 40703667. doi:10.1016/j.ctro.2025.101014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。